Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 2
2008 2
2009 1
2010 2
2012 4
2013 8
2014 16
2015 21
2016 17
2017 14
2018 9
2019 12
2020 18
2021 14
2022 11
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

141 results
Results by year
Filters applied: . Clear all
Page 1
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Cui N, Wang J, Wang Q, Zhang R, Yang J, Wu YL. Zhou Q, et al. Among authors: cheng y. Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038429 Clinical Trial.
PRDX4 and Its Roles in Various Cancers.
Jia W, Chen P, Cheng Y. Jia W, et al. Among authors: cheng y. Technol Cancer Res Treat. 2019 Jan 1;18:1533033819864313. doi: 10.1177/1533033819864313. Technol Cancer Res Treat. 2019. PMID: 31311441 Free PMC article. Review.
HDGF: a novel jack-of-all-trades in cancer.
Bao C, Wang J, Ma W, Wang X, Cheng Y. Bao C, et al. Among authors: cheng y. Future Oncol. 2014 Dec;10(16):2675-85. doi: 10.2217/fon.14.194. Future Oncol. 2014. PMID: 25236340 Review.
141 results